The short answer is yes: minoxidil works for roughly 60–70% of people with androgenetic (pattern) hair loss, backed by decades of randomized trials. The longer answer — how fast, how well, for whom, and what it does and doesn't do — is where the useful detail lives. Here's what the evidence actually shows.
Minoxidil was originally developed in the 1970s as an oral antihypertensive — a potent vasodilator for severe, treatment-resistant high blood pressure. Patients on it kept reporting an unusual side effect: new hair growth on the scalp, arms, and face. That observation led to a topical version approved by the FDA in 1988 for male pattern hair loss, and in 1992 for women.
The exact mechanism for hair growth is still not fully understood. It appears to open potassium channels in follicle cells, increase local blood flow to the dermal papilla, and — most importantly — prolong the anagen (growth) phase of the hair cycle while shortening the telogen (resting) phase. The net result is more hairs growing at any one time, and existing thin hairs becoming thicker and pigmented.
The best data on topical minoxidil comes from a landmark 48-week randomized trial by Olsen and colleagues published in the Journal of the American Academy of Dermatology, which compared 5% topical minoxidil to 2% and to placebo in 393 men with androgenetic alopecia. 5% minoxidil produced a mean hair count increase of about 45% over baseline at 48 weeks, and roughly 60–70% of men in the 5% group rated their regrowth as moderate to dense.
The American Academy of Dermatology's Guidelines of Care for Androgenetic Alopecia list topical minoxidil as a first-line, evidence-based treatment for both male and female pattern hair loss. More recent data on low-dose oral minoxidil, reviewed by Randolph and Tosti in JAAD in 2021 and in JAMA Dermatology in 2022, shows comparable and in some cases superior real-world response rates.
Translated into plain English: if you have early-to-moderate pattern hair loss and you use minoxidil correctly for a year, there's roughly a two-in-three chance you'll see a visible result you and someone else would recognize.
Topical 5% foam or liquid (Rogaine, generics). The most studied form. FDA-approved for men; FDA-approved for women as the 5% foam once daily (the twice-daily 2% was the original women's formulation). Cheap — often under $20/month as a generic. Downsides: needs to be applied once or twice a day indefinitely; can leave residue; occasionally irritates the scalp.
Topical 2% (women's formulation). Slightly less effective than 5% but with lower rates of scalp irritation and facial hair growth — a reasonable choice for women who are sensitive to the 5%.
Oral low-dose minoxidil (1.25–5 mg daily). Off-label in the U.S., but increasingly prescribed by dermatologists and nurse practitioners in 2024–2026. Convenience is the main selling point: one pill a day, no mess, no daily application ritual. Efficacy is comparable and adherence tends to be better. Tradeoffs: it's absorbed systemically, so some users notice mild lightheadedness, a faster resting heart rate, ankle swelling, or unwanted facial/body hair. Usually best for patients with no underlying cardiovascular disease — your prescriber will check your blood pressure and heart history before starting.
Minoxidil works most reliably for:
It works less well for advanced balding (Norwood 6–7), scarring alopecias (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia), and non-pattern causes of shedding like telogen effluvium, thyroid disease, iron deficiency, and post-COVID shedding. For those, the cause itself needs treating — minoxidil may still be added later, but alone it won't solve the problem.
Weeks 0–2: Nothing visible. You're just getting into the habit.
Weeks 2–8: Many users experience the "dread shed" — a temporary increase in shedding as weaker hairs in the telogen phase are pushed out while the drug synchronizes the follicles into a new cycle. This is a good sign, not a reason to quit. (See our full minoxidil shedding phase guide.)
Months 3–4: Shedding slows. You may not see regrowth yet, but the plateau is the first win.
Months 4–6: Early regrowth becomes visible. Usually finer, lighter hairs at first ("vellus"), which thicken over the following months.
Months 6–12: The real payoff window. Most visible density gain is here.
Month 12+: Maximum effect usually plateaus around 12 months. After that, maintenance-forever is the game. Our hair loss treatment timeline walks through this month-by-month in detail.
For men with androgenetic alopecia, the most evidence-supported regimen is minoxidil plus finasteride. They work through completely different mechanisms — minoxidil extends the growth phase, finasteride lowers DHT (the hormone miniaturizing follicles) — and the effects are additive. Real-world dermatology data suggests density at 12 months is meaningfully better on the combination than on either drug alone. Women under 40 sometimes combine minoxidil with spironolactone instead; postmenopausal women may use finasteride or dutasteride off-label. See our comparison on finasteride vs dutasteride and finasteride's timeline.
Topical minoxidil is generally well tolerated. The most common issues, per FDA DailyMed labeling and NIH MedlinePlus, are scalp irritation (especially with the propylene-glycol liquid; foam helps), unwanted facial hair in some women, and rare cases of lightheadedness. The dread shed is common but temporary.
Oral minoxidil adds a handful of systemic considerations: a mildly faster resting heart rate, ankle swelling in some users, occasional lightheadedness on standing, and more prominent unwanted hair growth (which some patients don't mind and some hate). Serious cardiovascular side effects at the low doses used for hair loss (1.25–5 mg) are rare in healthy adults but not zero — that's why it's prescribed, not over-the-counter.
If application isn't a barrier, topical 5% is cheap, available OTC, and well studied — a perfectly good first choice. Pick oral if: you've tried topical and hated the feel; you'd skip doses; you want more diffuse thickening; or you're already open to a quick telehealth visit with cardiovascular screening. Our deep-dive on oral vs topical minoxidil breaks the tradeoffs down in detail.
Minoxidil is one of the few hair-loss treatments with solid randomized-trial support behind it. About two out of three people with pattern hair loss will see a visible response if they use it correctly for a year. It's not magic, it's not a cure, and you have to keep taking it — but as a realistic first-line option, it earns its reputation.